Carl Heneghan, Director of the University of Oxford’s Centre of Evidence-Based Medicine, discusses recent developments in access to clinical-trial data.
The Pharmaceutical industry and drug regulators treat clinical data, submitted at the time of regulation, as confidential documents. At the same time, and to make matters worse, medical journals have “evolved into information laundering operations for the pharmaceutical industry.” This situation is dangerous for the public health and inhibits the advancement of medical science…………………………………. Read More at PLoS
